Cyr61, a member of the CCN (CTGF/Cyr61/NOV) family of growth regulators, is a secreted cysteine-rich proangiogenic factor that has been implicated in tumorigenesis. Previous studies have also demonstrated that Cyr61 is regulated by 17␤-estradiol (E 2 ) in the uterus. Therefore, we hypothesized that hormonal regulation of Cyr61 may be important in estrogen-dependent pathogenic processes such as breast tumorigenesis. Our study demonstrates that both Cyr61 messenger RNA and protein are induced by E 2 in MCF-7 mammary adenocarcinoma cells that primarily overexpress estrogen receptor ␣ (ER␣) in a dose-dependent and immediate early fashion. Cyr61 gene induction by E 2 is transcriptionally regulated by ER␣ as the antiestrogen, ICI 182,780, and actinomycin D blocked induction completely. In addition, Cyr61 is up-regulated in MCF-7 cells by epidermal growth factor (EGF) in an immediate early fashion as well. The functional relevance of steroid induction of Cyr61 in breast cancer cell growth is demonstrated by anti-Cyr61 neutralizing antibodies, which diminished E 2 and EGF-dependent DNA synthesis and dramatically reduced E 2 -driven cell proliferation by more than 70%. Most importantly, Cyr61 is overexpressed in 70% (28 of 40) of breast cancer patients with infiltrating ductal carcinoma and is localized exclusively to hyperplastic ductal epithelial cells. Moreover, the levels of Cyr61 protein are higher in breast tumors that are ER ϩ /EGF receptor ϩ than those that are ER Ϫ /EGF receptor ϩ , suggesting that estrogens may mediate Cyr61 expression in vivo. Collectively, our data suggest that Cyr61 may play a critical role in estrogen-as well as growth factor-dependent breast tumor growth. (Endocrinology 142:
growth factor (EGF) in an immediate early fashion as well. The functional relevance of steroid induction of Cyr61 in breast cancer cell growth is demonstrated by anti-Cyr61 neutralizing antibodies, which diminished E 2 and EGF-dependent DNA synthesis and dramatically reduced E 2 -driven cell proliferation by more than 70%. Most importantly, Cyr61 is overexpressed in 70% (28 of 40) of breast cancer patients with infiltrating ductal carcinoma and is localized exclusively to hyperplastic ductal epithelial cells. Moreover, the levels of Cyr61 protein are higher in breast tumors that are ER ϩ /EGF receptor ϩ than those that are ER Ϫ /EGF receptor ϩ , suggesting that estrogens may mediate Cyr61 expression in vivo. Collectively, our data suggest that Cyr61 may play a critical role in estrogen-as well as growth factor-dependent breast tumor growth. (Endocrinology 142: 2540 -2548, 2001) B REAST CANCER IS the leading cause of death in nonsmoking women today and with a rising incidence continues to be a major health concern in the United States (reviewed in Ref. 1) . Although a number of genetic and environmental factors contribute to the development of mammary epithelial neoplasia and ultimately malignancy, tumorigenesis appears to be under hormonal regulation (reviewed in Ref. 2 ). This is due in part to the actions of estrogen on the induction of growth factors, transcription factors, and cell cycle regulators that, along with genetic alterations, are largely responsible for breast carcinogenesis (reviewed in Ref. 3 ).
An emerging group of growth factor-regulated immediate-early genes that mediate diverse roles in development, cell proliferation, and tumorigenesis collectively belong to the CCN (CTGF/Cyr61/Cef10/NOVH) family. Cyr61, a prototypical member of this family, was originally identified by differential hybridization screening of a complementary DNA (cDNA) library of serum-stimulated BALB/c 3T3 fibroblasts (4). Cyr61 is not expressed in quiescent fibroblasts, but is transcriptionally activated within minutes after stimulation by serum, epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor, transforming growth factor-␤, and 12-O-tetradecanoylphorbol 13-acetate (4 -7). Rapid and transient induction of Cyr61 by vitamin D 3 , tumor necrosis factor-␣, as well as interleukin-1 has also been reported in human fetal osteoblasts (8) . Cyr61 is a secreted, cysteine-rich heparin-binding protein that associates with the cell surface and the extracellular matrix, biochemical features that resemble the Wnt-1 protooncogene and a number of known growth factors (9) . The human Cyr61 cDNA encodes a protein 379 amino acids (aa) in length with a molecular mass of 42 kDa, and the gene is located on the short arm of chromosome 1 (1p22-31) (10, 11) . All CCN proteins 1) display a high degree of conservation among family members and across species, 2) are cysteine-rich and structurally similar to extracellular matrixassociated molecules, 3) are composed of multifunctional modular domains, and 4) have been shown to mediate functions as diverse as cell adhesion, cell migration, mitogenesis, cell survival, and differentiation (reviewed in Ref. 12 ). More specifically, Cyr61 has been shown to be directly involved in a number of developmentally regulated processes such as angiogenesis and chondrogenesis (13, 14) .
In addition to growth factors, Cyr61 is regulated by 17␤-estradiol (E 2 ) in ovariectomized rat uteri in vivo (15) . Given that estrogen induction of growth factors appears to be critical to breast tumorigenesis, we sought to determine whether Cyr61 is induced by E 2 in hormone-responsive MCF-7 mammary adenocarcinoma cells. In addition, the role of Cyr61 in mammary tumor epithelial cell growth was addressed by determining the effects of anti-Cyr61 neutralizing antibodies on hormone-dependent DNA synthesis and cell proliferation. Finally, estrogen receptor (ER)-positive and -negative tumor lysates from a cohort of patients with invasive ductal carcinomas, the most common form of breast cancer, were screened for Cyr61 protein expression and compared with autologous healthy mammary tissue controls to ascertain the relevance of hormonal regulation of Cyr61 in breast carcinogenesis.
Materials and Methods Materials
17␤-Estradiol (E 2 ), dihydrotestosterone, (DHT), dexamethasone (DEX), cycloheximide (Chx), and actinomycin D were purchased from Sigma-Aldrich Corp. (St. Louis, MO); the progesterone receptor (PR) agonist, R5020, was obtained from NEN Life Science Products (Boston, MA); epidermal growth factor (EGF) and heparin-binding EGF (HB-EGF) were purchased from R&D Systems (Minneapolis, MN); ICI 182,780 was provided by AstraZeneca Pharmaceuticals (Wilmington, DE), and 2-hydroxyflutamide was a donation from Ligand Pharmaceuticals, Inc. (San Diego, CA).
Cell culture
MCF-7 and MDA-MB-231 adenocarcinoma cell lines were obtained from American Type Culture Collection (Manassas, VA) and propagated in DMEM/Ham's F-10 medium containing 10% FBS, 100 U/ml penicillin, 100 g/ml streptomycin, and 2 mm Glutamax (Life Technologies, Inc., Gaithersburg, MD). For steroid and/or growth factor treatments, cells were cultured in phenol-red free DMEM/F-12 medium containing 2% charcoal-stripped FBS (HyClone Laboratories, Inc., Logan, UT).
Cyr61 antibodies
Two anti-Cyr61 polyclonal antisera were generated at the Louisiana State University Medical Center Core Facilities (Baton Rouge, LA) to peptides corresponding to aa 163-229 or 371-381 of the human Cyr61 as antigens. Peptides were coupled to keyhole limpet hemocyanin and injected into female New Zealand White rabbits. After preliminary screening of crude antisera by Western analysis of human uterine smooth muscle cell lysates, which contain high basal levels of Cyr61 protein, polyclonal antibodies were purified by affinity chromatography using their respective peptides as the immunoabsorbent.
Study subjects and tissue procurement
Breast tumor biopsies and matched normal mammary tissue specimens were obtained from Clinomics, Inc. (Pittsfield, MA), after obtaining informed patient consent and internal review board approval. Patients (n ϭ 40) were between the ages of 42-68 yr (average, 54 yr) and had been diagnosed with stage II invasive ductal carcinoma after histological examination. In addition, tumors were classified as ER ϩ /EGF receptor ϩ (EGFR ϩ ; n ϭ 20) or ER Ϫ /EGFR ϩ (n ϭ 20) by immunohistochemical staining of formalin-fixed tumor biopsies using monospecific anti-ER and anti-EGFR antibodies. Tissue specimens were immediately frozen in liquid nitrogen after surgery for protein extraction or were fixed in 10% neutral-buffered formalin for in situ hybridization.
Northern blotting for Cyr61
Total cellular RNA was isolated from cultured adenocarcinoma cells by guanidium isothiocyanate lysis followed by phenol/chloroform extraction. Subsequently, total cellular RNA (20 g) was subjected to electrophoresis in an 1% agarose gel containing 1 m formaldehyde and transferred onto nylon membranes by capillary electrophoresis. A 0.41-kb human Cyr61 cDNA fragment was radiolabeled with [␣-32 P]deoxy-CTP (3000 Ci/mmol) using the random primer technique (Rediprime II, Amersham Pharmacia Biotech, Arlington Heights, IL) and used as the hybridization probe. Relative levels of Cyr61 were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) after reprobing membranes with a 32 P-radiolabeled oligonucleotide according to manufacturer's protocol (end labeling kit, Life Technologies, Inc.).
Protein extraction and immunoblotting for Cyr61
Tissue protein extracts were prepared from breast tumors and matched normal mammary tissue specimens by homogenization in 50 mm Tris (pH 8.0), 250 mm NaCl, 1.0% Nonidet P-40, 1.0% Triton-X 100, 2.0% SDS, 0.5% deoxycholate, 1 mm EDTA, and protease inhibitor cocktail containing 10 g/ml pepstatin, aprotinin, and leupeptin (SigmaAldrich Corp.). Protein extracts (20 g) were subjected to SDS-PAGE under reducing conditions in 10% bis-acrylamide and electrophoretically transferred to a polyvinyl difluoride membrane (Immobilon-P, Bio-Rad Laboratories, Inc., Redding, CA). Membranes were blocked with 5% dry milk on TBS/0.1% Tween-20 and incubated with anti-Cyr61 pAb (10 g/ml). Primary antibody binding was detected using a donkey antirabbit IgG antibody conjugated to horseradish peroxidase and an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech). All immunoblots were subsequently reprobed with 1 g/ml anti-pan-cytokeratin monoclonal antibodies (Sigma-Aldrich Corp.) to verify equivalent protein loading.
In situ hybridization
For riboprobe synthesis, a 0.28-kb human Cyr61 cDNA fragment was positionally cloned into the EcoRI and HindIII sites of pGEM4Zf-plasmid (Promega Corp., Madison, WI) to generate pGEM4Zf-/Cyr61. Radiolabeled [
35 S]UTP sense and antisense complementary RNA transcripts were transcribed in vitro with T3 and T7 RNA polymerases, respectively, using the Gemini Riboprobe system (Promega Corp.). In situ hybridization was performed as described previously (16), using formalin-fixed breast tumor biopsies and matched normal mammary specimens.
Cyr61 neutralization assays with anti-Cyr61 antibodies
Polyclonal antibodies were raised to a 65-aa peptide corresponding to the central domain of Cyr61, which was selected based on a lack of homology to other CCN family members and the published effectiveness of the antibodies in neutralizing bFGF-mediated DNA synthesis in human microvascular endothelial cells (17) . The antibodies were affinity purified and assayed for specificity by Western blot analysis using E 2 -treated MCF-7 whole cell lysates. A major band was detected at 42 kDa, which is the molecular mass of Cyr61, along with a minor band at 77 kDa. For DNA synthesis, MCF-7 and MDA-MB-231 cells were treated with 0.3 nm E 2 , 20 ng/ml EGF, or 20 ng/ml HB-EGF in the presence or absence of 10 g/ml anti-Cyr61 antibodies for 18 h, and bromodeoxyuridine (BrdU) incorporation was measured using the BioTrak enzyme-linked immunosorbent assay kit (Amersham Pharmacia Biotech, Arlington Heights, IL) according to the manufacturer's instructions. For cell proliferation assays, MCF-7 cells were cultured in 2% charcoalstripped FBS medium containing 0.3 nm E 2 or 20 ng/ml EGF for 5 days in the presence or absence of 10 g/ml of anti-Cyr61-neutralizing antibodies or nonimmune IgG at 37 C in 5% CO 2 . After steroid or growth factor treatment, monolayers were trypsinized, combined with cells in the culture supernatant, and counted in a Coulter Multisizer II counter (Coulter Corp., Miami, FL).
Densitometric and statistical analysis of Cyr61 levels
Densitometric analysis of Cyr61 messenger RNA (mRNA) levels was accomplished with a PhosphorImager and image quantitation software (Molecular Dynamics, Inc., Sunnyvale, CA). Numerical values are based on the relative volume of the radioactive band, and the level of Cyr61 was normalized to the level of GAPDH. Cyr61 protein levels detected by Western analysis were quantitated by densitometric analysis using a molecular imager (Bio-Rad Laboratories, Inc.). Numerical values are based on the relative OD of the band, and the level of Cyr61 was normalized to the level of cytokeratin. All experiments were repeated at least three times. Arbitrary units derived from densitometric measurements of RNA and protein bands were analyzed using SAS statistical software (SAS Institute, Inc., Cary, NC) for significance using either one-way ANOVA for a factorial experimental design or paired t test. The multicomparison significance level for the one-factor ANOVA was 0.05. If significance was achieved by one-way analysis, post-ANOVA comparison of means was performed using Scheffé's F tests (18) .
Results

Cyr61 is selectively up-regulated by E 2 in MCF-7 mammary adenocarcinoma cell lines
Analysis of estrogen regulation of Cyr61 was assessed by monitoring the expression pattern of Cyr61 in E 2 -responsive MCF-7 cells. Similar to serum and growth factors, E 2 upregulated Cyr61 transcript and protein in an immediate-early and dose-dependent (EC 50 ϭ 0.6 nm) fashion (Fig. 1, A-D) . In addition to E 2 , Cyr61 was up-regulated by 10 nm DHT, but not by DEX or the progestin, R5020, in MCF-7 cells (Fig. 2,  A and B) . Analysis of Cyr61 mRNA levels in MCF-7 cells at 0, 0.5, 1.0, 2.0, 4.0, and 8.0 h of either DEX or R5020 treatment did not result in increased expression (data not shown). However, in T47D cells that overexpress PR, R5020, but not DEX, stimulation induced Cyr61 (Sampath, D., et al., manuscript in preparation). In MCF-7 cells, DHT induction occurred in an immediate-early fashion, with maximal expression occurring within 1 h and was completely inhibited by the androgen receptor (AR) antagonist, 2-hydroxyflutamide, indicating that the up-regulation of Cyr61 was dependent on AR activity (data not shown). However, the maximum level of Cyr61 protein up-regulated by 10 nm DHT in MCF-7s was less than half of that observed with 1 nm E 2 (Fig. 2B) . Interestingly, in MDA-MB-453 adenocarcinoma cell lines that overexpress AR, Cyr61 was induced more than 8-fold by DHT in an immediate-early fashion as well (Sampath, D., et al., manuscript in preparation). Therefore, although Cyr61 is up-regulated by androgens and progestins in cell lines that overexpress AR and PR, respectively, estrogen is the primary inducer of this gene in MCF-7 cell lines.
Cyr61 is regulated by ER␣ at the transcriptional level
To determine whether Cyr61 induction in MCF-7 cells was ER dependent we analyzed the effect of a receptor antagonist on expression. Given that ER␣ and ER␤ can vary between subclones of breast tumor cells, we first determined the rel- ative levels of both receptors by quantitative RT-PCR. In the MCF-7 cells used for our experiments, ER␣ is exclusively overexpressed, and ER␤ is detectable only at very low levels (data not shown) (19) . Induction of Cyr61 by E 2 in MCF-7 is primarily mediated through ER␣, as the antiestrogen, ICI 182,780, completely abrogated expression (Fig. 3) . Furthermore, in ER Ϫ MDA-MB-231 adenocarcinoma cells expression of Cyr61 was not enhanced by E 2 , but was induced upon EGF or HB-EGF stimulation, demonstrating that ER was required for Cyr61 induction (data not shown). Additionally, inhibition of Cyr61 up-regulation was not observed in MCF-7 cells cotreated with 10 g/ml Chx and 10 nm E 2 , suggesting that de novo protein synthesis was not required for steroid induction (Fig. 3, A and B) . In contrast, significant overexpression of Cyr61 was observed upon cotreatment with Chx and E 2 compared with E 2 treatment alone (Fig. 3B) . These increases in mRNA levels are often observed with Chx cotreatment, which may be due to the lack of synthesis of mRNA decay or turnover factors. However, cotreatment of E 2 with 1 g/ml actinomycin D completely blocked steroid induction, implying that ER␣ mediates Cyr61 expression at the transcriptional level (Fig. 3, A and B) . Therefore, Cyr61 is primarily induced by estrogen through ER␣ in an immediate-early fashion in MCF-7 cells at the transcriptional level.
Cyr61 is up-regulated in human breast cancer tumors
Given that Cyr61 is induced in breast carcinoma cell lines in vitro, we investigated whether overexpression is observed in breast tumors in vivo. Indeed, a 3.5-to 6-fold increase in Cyr61 protein levels was observed in 70% (28 of 40) of breast tumor lysates generated from patients with stage II invasive ductal carcinoma compared with autologous healthy mammary tissue controls (Fig. 4A and 4B) . Interestingly, Cyr61 levels were significantly higher in tumors that were ER ϩ / EGFR ϩ (n ϭ 20) compared with those in ER Ϫ /EGFR ϩ tumors (n ϭ 20; Fig. 4C ). However, the overall percentage of Cyr61 positive breast tumors did not vary significantly between ER ϩ (75%, 15 of 20) and ER-(65%, 13 of 20) subsets (Fig. 4D) . Furthermore, the results of in situ hybridization studies revealed that Cyr61 is selectively overexpressed in hyperplastic luminal and stroma-invading epithelial cells contained within tumors isolated from patients with invasive ductal carcinoma (Fig. 5, B and F) . No expression of Cyr61 was observed in the ductal epithelium or surrounding paranchymal cells (i.e. myoepithelial, adipocytes, and fibroblasts) in adjacent healthy mammary tissue (Fig. 5 , A and E).
E 2 sustains EGF induction of Cyr61 in MCF-7 cell lines
As Cyr61 has been classically defined as a growth factorresponsive immediate-early gene, we sought to determine whether E 2 synergized with EGF to increase Cyr61 expression in MCF-7 cell lines. Similar to our initial observations with E 2 , treatment of MCF-7 cells with 10 ng/ml EGF resulted in a greater than 5-fold increase in Cyr61 mRNA levels in an immediate-early fashion (Fig. 6, A and B) . However, cotreatment with 10 ng/ml EGF and 10 nm E 2 resulted in sustained expression beyond 2 h compared with that observed for E 2 or EGF treatment alone (Fig. 6, C and D) . Thus, the combination of E 2 and EGF appears to have a synergistic effect in enhancing Cyr61 expression and may in part explain the overexpression of Cyr61 in those tumors that are estrogen and EGF receptor positive.
Cyr61 is required for steroid-and growth factor-dependent DNA synthesis and cell proliferation in breast carcinoma cells
To determine the function of Cyr61 in the context of steroid-and growth factor-dependent growth, DNA synthesis and cell proliferation were monitored in the presence of anti-Cyr61 polyclonal antibodies. Treatment of MCF-7 cells with 10 g/ml anti-Cyr61 antibodies decreased DNA synthesis induced by 0.3 nm E 2 , 20 ng/ml EGF, or 20 ng/ml HB-EGF by 50%, 44%, and 63%, respectively (Fig. 7, A and B, and data not shown). In addition, anti-Cyr61 antibodies blocked EGF-induced DNA synthesis in MDA-MB-231 cells (data not shown). Controls for the BrdU assay included cotreatment with 10 g/ml nonimmune IgG, which had no effect, and 10 g/ml blocking peptide, which completely reversed the neutralizing effects of anti-Cyr61 (Fig. 7, A-C) . Therefore, Cyr61 appears to be necessary for initiation of the cell cycle by effecting steroid-and growth factor-mediated entry into S phase. Therefore, E 2 -and EGF-dependent MCF-7 cell proliferation was monitored to directly determine the role of Cyr61 in cell growth. Increased MCF-7 cell proliferation induced by E 2 was observed in a dose-response fashion, with an EC 50 of 10 pm and maximum cell growth achieved at 300 pm in a 5-day treatment period (data not shown). Anti-Cyr61 polyclonal antibodies (10 g/ml) inhibited E 2 -dependent cell growth by 72% and EGF-dependent cell growth by 40% over a 5-day treatment period (Fig. 7, A and  B) . Furthermore, continued exposure of MCF-7 cells to 10 and 300 pm E 2 over a 5-day period resulted in significant increases (3-to 4-fold) in Cyr61 protein levels compared with basal levels when detected by Western analysis (see inset in Fig. 7B ). These results indicate that prolonged treatment of MCF-7 cells with E 2 increases the sensitivity of Cyr61 induction and/or augments protein stability. It also implies that submaximal levels of Cyr61 protein are adequate for optimal tumor cell growth when driven by E 2 under these in vitro conditions. The antiproliferative effect of the neutralizing antibodies was not due to cytotoxicity, because treated MCF-7 cells did not take up trypan blue (data not shown). Thus, Cyr61 is required for E 2 -and EGF-mediated cell proliferation of MCF-7 cells in vitro.
Discussion
The development and progression of breast cancer are purported to be orchestrated by a sequential process of 1) activation of oncogenes or loss of tumor suppressor genes, 2) growth priming of tumor cells by estrogen through the induction of cell cycle regulatory genes, transcription factors, and cell-adhesion molecules, and 3) the autocrine and/or paracrine action of growth factors such as EGF, insulin-like growth factors, transforming growth factors-␣ and -␤, platelet-derived growth factors A and B, and FGF (reviewed in Ref.
3). Thus, ovarian sex steroid and/or growth factor target genes in mammary epithelial cells that act as local mediators may be critical for neoplastic generation and subsequently tumorigenesis. Given that, we provide evidence that Cyr61, a serum-inducible immediate-early gene, is an estrogen target gene that is transcriptionally regulated and required for hormone-dependent cell proliferation in human MCF-7 mammary adenocarcinoma cells. The significance of these results is underscored by the observation that in 70% of breast tumor biopsies isolated from patients with Ϫ /EGFR ϩ (B). Detection of Cyr61 proteins (A and B) was accomplished using an affinity-purified anti-Cyr61 polyclonal antibody and enhanced chemiluminescence as described in Materials and Methods. NSP, Nonspecific protein that was detected with anti-Cyr61 antibodies. C, The fold expression of Cyr61 was calculated by dividing the relative levels of Cyr61 normalized to cytokeratin in breast tumor lysates by the levels in autologous healthy mammary controls. Values are the mean Ϯ SD for 20 patients. D, The percentage of Cyr61-positive (ϩ) breast tumors that were ER ϩ and ER Ϫ was determined by the dividing the number of tumor protein lysates that overexpressed Cyr61, as determined by Western blotting and comparison with the matched control, by the total number of tumor specimens analyzed. *, Significant increase in levels compared with normal matched tissue controls (P Ͻ 0.0001).
stage II invasive ductal carcinoma, Cyr61 was up-regulated in hyperplastic ductal/luminal epithelial cells compared with autologous healthy mammary tissue controls. Moreover, the levels of Cyr61 protein were greater in those tumors that were ER ϩ /EGFR ϩ than in those that were ER Ϫ /EGFR ϩ , suggesting that estrogen in conjunction with growth factors may regulate Cyr61 expression in vivo and during carcinogenesis. It is noteworthy that other steroid hormones, such as progesterone and DHT in mammary adenocarcinoma cell lines that overexpress PR and AR, respectively, induce Cyr61 as well, implying that it may be a general mediator of hormone-dependent tumorigenesis.
Based on previous studies, the role of Cyr61 in mammalian cell development (13, 20) suggests that aberrant expression may predispose cells toward dysregulated growth, such as in tumorigenesis. Indeed, overexpression of Cyr61 has been observed in several human cell lines derived from human bladder papilloma, colon adenocarcinoma, melanoma, and meduloblastoma (14) . In some instances Cyr61 is thought to promote tumorigenesis. For example, transfection of a Cyr61 expression vector into the gastric adenocarcinoma cell line RF-1, which does not express Cyr61, increases these cells' tumorigenicity in vivo (14) . Conversely, Cyr61 is shown to be down-regulated in the epithelium of prostate cancer biopsies, uterine smooth muscle cells of leiomyomas, and the embryonal-rhabdomyosarcoma cell line, RD, suggesting that it may also function as a tumor suppressor or regulate cellular differentiation (21) (22) (23) . Interestingly, rCop1, a recently identified member of the CCN family that shares a high degree of homology to Cyr61, has been shown to be a negative regulator of cell transformation when overexpressed and thus behaves similarly to tumor suppressors (24) . Therefore, depending on the cell and tumor types, variable expression of Cyr61 may result in either positive or negative selection for dysregulated cell growth.
As our studies demonstrate that anti-Cyr61-neutralizing antibodies can inhibit E 2 as well as EGF-dependent DNA synthesis and cell proliferation by more than 50%, Cyr61 appears to play a novel and important role in mammary adenocarcinoma cell growth in vitro. The immediate-early kinetics of Cyr61 are consistent with other growth-promoting genes that are regulated by estrogen and required for epithelial cell proliferation (3). As a ligand for the integrin receptors ␣ v ␤ 3 , II b 3 a , and ␣ 5 ␤ 1 (25) (26) (27) , it is plausible that Cyr61 may emit its growth effects through integrin signal transduction or through an as yet to be identified cognate receptor that may be expressed on breast tumor epithelial cells. In addition, as Cyr61 is a growth factor-binding protein and augments growth factor-dependent DNA synthesis (17, 28) , it may promote mammary tumor cell growth by directly interacting with certain growth factors to enhance their bioactivity. Thus, up-regulation of Cyr61 in ER ϩ breast tumors by E 2 may augment the bioactivity of growth factors that, through a positive feedback, would, in turn, result in waves of Cyr61 expression and continued cell proliferation.
Invasive ductal carcinoma (IDC) is the most common type of breast cancer and accounts for 80% of known cases (1) . Overexpression of Cyr61 protein in 70% of the IDC patients analyzed in this study suggests that it may be an important mediator of breast tumor development and growth in vivo. Interestingly, a recent report by Tsai et al. demonstrates that Cyr61 mediates MCF-7 cell migration in an ␣ v ␤ 3 -dependent manner and is overexpressed in a subset of IDC tumors, further corroborating our patient observations (29) . Moreover, the increased levels of Cyr61 protein in ER ϩ breast tumors suggest that it may contribute to estrogen-driven tumorigenesis in vivo. Overexpression of Cyr61 in breast tumors may be due to the ability of E 2 to synergize with growth factors such as EGF and HB-EGF to sustain Cyr61 expression. Alternatively, mutations within estrogen response elements or growth factor-activated response elements that result in aberrant promoter activity, gene amplification, or increased mRNA stabilization may also lead to Cyr61 overexpression. Growth factor up-regulation of Cyr61 in steroid-sensitive breast tumors may also predispose a subset of tumor epithelial cells toward continued dysregulated proliferation, as their growth becomes hormone-independent or metastatic in the malignancy process. To summarize, as illustrated in Fig. 8 , Cyr61 expression in breast cancer may conceptually orchestrate multiple activities to 1) promote tumor cell proliferation in an autocrine and/or paracrine fashion by augmenting growth factor activity (17, 28) or transmitting proliferative signals via integrin receptors (25, 26) , 2) coordinate tumor epithelial migration and progression chemokinetically (29) , and 3) regulate tumor neovascularization in a paracrine fashion as a proangiogenic factor (14, 25) . The modular domain structure of Cyr61 and its localization to the extracellular matrix may account for its ability to concomitantly dictate multiple functions during tumorigenesis, such as cell proliferation and migration.
In conclusion, Cyr61 is regulated by E 2 in an immediateearly fashion and is essential for hormone-dependent DNA Given that Cyr61 is a proangiogenic factor and a growth regulator, it is hypothesized that up-regulation of Cyr61 in tumor epithelial cells by E 2 and EGF may drive tumorigenesis in several concerted modes: 1) promote tumor cell proliferation in an autocrine and/or paracrine fashion by either augmenting growth factor bioactivity or 2) emit proliferative signals via ␣/␤ integrin receptors or Cyr61-specific receptors, 3) coordinate tumor epithelial cell migration as a chemokinetic factor, and 4) regulate endothelial recruitment tumor neovascularization in a paracrine fashion through an ␣ v ␤ 3 -dependent mechanism.
synthesis and cell proliferation in MCF-7 breast adenocarcinoma cells in vitro. In addition to promoting angiogenesis and cell migration, overexpression of Cyr61 selectively in the ductal epithelium of breast tumors may provide a locally mediated growth advantage through an autocrine and/or paracrine fashion during hormone-driven tumorigenesis and in a paracrine mode during tumor progression. Cyr61 may be a useful diagnostic marker for invasive ductal carcinomas, whereas inhibiting its expression or bioactivity may prove therapeutically efficacious in the treatment or prevention of breast cancer.
